Overview of Lostaprolol

Quick Facts

Property	Description
Active ingredient	Bisoprolol fumarate
Form	Oral tablet (film-coated)
Pharmacological class	Beta-adrenergic blocking agent (Beta-blocker)
Common use	Cardiovascular stabilization
Origin	Synthetic compound

Lostaprolol: What Type of Cardiovascular Medicine is It?

Lostaprolol is a pharmaceutical preparation whose active substance is Bisoprolol fumarate, classified as a β-adrenergic blocking agent, more commonly known as a beta-blocker. It is a synthetic compound within the Second generation beta-blocker group, categorized as a sympatholytic agent. This classification means it works to counteract the stimulating effects of the sympathetic nervous system on the heart and blood vessels, specifically the action of catecholamines like adrenaline.

Its distinguishing feature is its high relative selectivity for the heart's β1-adrenergic receptors, a property known as cardioselectivity. This property is clinically recognized for offering a more focused therapeutic profile compared to older, non-selective analogues.

Understanding the Composition and Dosage Form

Lostaprolol is a single active ingredient product (monotherapy formulation) where the therapeutic action is solely driven by the Bisoprolol fumarate molecule. It is administered via the oral route and is typically presented as a solid, usually film-coated tablet.

The active substance is commonly supplied as a racemic mixture, a feature common to the synthesis of many beta-blockers. Pharmacological studies support that Bisoprolol is recognized for its high bioavailability and intermediate duration of action, which supports its utility as a potential once-daily treatment. The tablet preparation combines this active component with standard pharmaceutical excipients necessary for stability, structure, and controlled release.

What is the General Physiological Purpose of Lostaprolol?

The overarching physiological purpose of Lostaprolol is to stabilize heart function by significantly reducing its overall workload. It achieves this by acting as a competitive β1-adrenergic antagonist, which results in negative chronotropy (slowing the heart rate) and negative inotropy (moderating the force of contraction).

By lessening both the speed and the effort of the heart, Lostaprolol minimizes the myocardial demand for oxygen. This fundamental effect ensures the cardiovascular system operates more efficiently. Research confirms that this mechanism contributes to the regulation of vascular tone by inhibiting renin release in the kidneys, a multifaceted action supported by pharmacological studies.

What side effects are possible with Lostaprolol?

Lostaprolol (Bisoprolol fumarate) is associated with adverse reactions that are classified by frequency and the physiological systems affected, in alignment with regulatory prescribing information. The safety profile is established through clinical data providing classifications such as very common, common, uncommon, and rare. These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.

Documented Adverse Reactions and Frequency

Adverse effects involving the Cardiac system are prominent. A Very Common reaction, defined as occurring in 1 out of 10 people or more, is bradycardia (a significantly slowed heart rate) in patients treated for chronic heart failure. Common reactions (occurring in up to 1 in 10 people) include hypotension, a feeling of coldness or numbness in the extremities, and gastrointestinal disturbances (nausea, vomiting, diarrhoea, constipation). Common effects like dizziness and fatigue are noted as often being transient, especially occurring at the beginning of the therapy.

Serious Safety and Population-Specific Considerations

The official label highlights that the worsening of pre-existing heart failure is a documented serious adverse reaction. A critical safety constraint applies regardless of administration: abrupt cessation of therapy, particularly in patients with underlying coronary artery disease, is associated with the risk of exacerbation of angina pectoris or myocardial infarction.

Specific safety patterns are stated for certain groups:

Diabetic Patients: The medication may mask the symptoms of hypoglycaemia, such as the increased heart rate that typically serves as a warning sign.
Bronchospastic Disease: Due to the risk of bronchospasm, the use of beta-blockers is generally advised against in individuals with conditions like bronchial asthma.

Overdose and Emergency Response

Lostaprolol Overdose and when to seek help

The regulatory overdose profile for Lostaprolol (Bisoprolol fumarate) defines the manifestations and the required immediate emergency response based on official label information. Overdose typically presents as an exaggeration of the known pharmacological effects, severely impacting the cardiovascular and central nervous systems.

Element	Regulatory Statement
Documented Manifestations	Overdose is typically characterized by an exaggeration of effects, including profound bradycardia (excessively slow heart rate), severe hypotension (abnormally low blood pressure), and acute signs of cardiac failure. Other documented manifestations include bronchospasm, hypoglycemia (low blood sugar), and atrioventricular (AV) block.
Severe Outcomes	Potential life-threatening outcomes noted in official documents include the progression to cardiogenic shock, coma, and severe CNS compromise such as seizures or deep lethargy.
Emergency Action Required	Seek immediate medical attention or call emergency services if an overdose is suspected. Urgent action is mandated if the individual has collapsed, is experiencing severe trouble breathing, or cannot be awakened.
Management Note	No specific antidote is known for this overdose. Management is defined as symptomatic and supportive treatment, including necessary measures such as the use of sympathomimetic agents or the correction of hypoglycemia. Due to the drug’s duration of action, close cardiac monitoring and hospital observation may be required.

This profile dictates the immediate response required. The primary focus of official management is mitigating the life-threatening physiological disturbances since treatment is strictly supportive. Limited data indicate the compound is not effectively removed by hemodialysis.

Therapeutic Uses of Lostaprolol

What Lostaprolol Treats: Main Uses and Benefits

Lostaprolol (Bisoprolol fumarate) is commonly used as a component of therapy that plays a role in cardiac stabilization and the long-term management of cardiovascular risk across several chronic domains. The medication is applied in therapeutic areas that involve sustained physiological stress on the heart.

The drug is relevant for use in situations involving heightened physiological activity and chronic conditions, including the sustained management of high blood pressure (hypertension), relief for Chronic Stable Angina Pectoris, control of certain supraventricular arrhythmias, and supportive therapy for Chronic Heart Failure (HFrEF) in its stable state. This usage pattern helps address symptom clusters that may become intense or disruptive, such as frequent palpitations and recurrent chest pain.

“This supportive role is considered relevant for assisting with long-term clinical stability and contributes to easing the symptom load in chronic conditions.”

The primary benefit is its role in supporting the long-term management of cardiovascular risk. This supports a reduction in the severity of symptomatic episodes, assists with maintaining functional stability, and supports patients during episodes of heightened discomfort.

Quick Fact: Relief for Cardiovascular Symptom Clusters

Benefit Area	Clinical Scenario
Symptom Easing	Helps address symptoms related to frequent palpitations and irregular heart rhythms.
Condition Management	Supports the long-term control of hypertension and chronic stable angina.
Functional Support	Contributes to maintaining functional stability and supports the patient during symptomatic episodes.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Lostaprolol

This section summarizes the official eligibility profile based on governmental regulatory documents, defining patient populations who must not use the medicine (contraindications) and those requiring restricted use.

Populations Excluded from Use (Contraindicated)

Category	Regulatory Status
Hypersensitivity	Contraindicated in patients with known hypersensitivity to Lostaprolol or any components.
Acute Cardiac Conditions	Contraindicated for acute or decompensated heart failure, cardiogenic shock, and severe bradycardia (slow heart rate).
Conduction Disorders	Contraindicated for second or third degree atrioventricular (AV) block and sick sinus syndrome (unless a permanent pacemaker is in place).
Severe Respiratory Disease	Contraindicated for severe bronchial asthma or severe chronic obstructive pulmonary disease (COPD).

Restricted or Conditional Use

Organ Function: Patients with severe hepatic or renal impairment may require dose adjustment and close monitoring, as defined in official regulatory labeling.
Metabolic Status: Use requires special caution in patients with diabetes mellitus, as the medicine may mask signs of acute hypoglycemia.
Age-Group Eligibility: Safety and efficacy are not established in the pediatric population. In geriatric patients, a cautious approach, often with a lower starting dose, is typically advised.
Pregnancy/Lactation: Use is not recommended during pregnancy unless the potential benefit outweighs the documented risk to the fetus/neonate. Use during breastfeeding is generally not advised.

What should I know about interactions with other medicines?

️ Interactions with other medicines and products — official regulatory information for Lostaprolol

Interaction Scope

Medicinal product categories with documented interactions include other beta-blocking agents, Verapamil/Diltiazem-type calcium channel blockers, Catecholamine-Depleting Agents, Class I Antiarrhythmics, and Insulin or Oral Antidiabetic Drugs. Specific interacting medicines explicitly listed include Clonidine and Rifampicin.

The official documented mechanistic basis includes Additive Pharmacodynamic Effects on cardiac function and Pharmacodynamic Masking of hypoglycemia symptoms. Pharmacokinetic data documents PK Insensitivity, noting Lostaprolol is not metabolized by CYP2D6 and is insensitive to Cimetidine.

A procedural timing rule requires that Lostaprolol must be discontinued for several days before the withdrawal of Clonidine to prevent documented rebound hypertension risk. Population-specific notes confirm that in severe renal or hepatic impairment, the plasma half-life is officially documented as being increased up to threefold, escalating exposure risk. Restriction: Co-administration with other beta-blockers is strictly avoided; combination with Verapamil/Diltiazem-type agents is generally not recommended.

Interaction Classifications (High-Level)

Interaction severity classifications range from Contraindicated Combination (other beta-blockers) to Generally Not Recommended (Verapamil/Diltiazem, Clonidine). Regulatory constraints are primarily pharmacodynamic (additive cardiac effects, masking symptoms) and procedural (Clonidine withdrawal timing), as defined in official government documentation.

Connection to the overall interaction profile

Regulatory documents define the interaction structure primarily through the risk of additive pharmacodynamic effects, leading to prohibitions against co-administering certain cardiovascular agents. The profile formally notes the lack of interaction with food and the CYP2D6 enzyme, but includes specific constraints such as the mandatory timing separation for Clonidine withdrawal. Constraints are extended to populations with renal and hepatic dysfunction where decreased clearance officially increases exposure risk.

Mechanism of Action

Selective beta1-Adrenergic Receptor Antagonism

Lostaprolol functions by competitively blocking beta1-adrenergic receptors, which are primarily located in the heart. This action prevents the binding of endogenous stress hormones like epinephrine, thereby reducing sympathetic nervous system activity upon the heart muscle and conduction tissue.

Modulation of Cardiac Signaling Cascades

The blockade of beta1-receptors interrupts the Gs protein-adenylate cyclase-cAMP signaling pathway. This early molecular step is modified to decrease the subsequent activation of Protein Kinase A and the resulting influx of calcium ions into cardiac cells. This results in predictable adjustments of cardiac cell activity.

Reduction of Renin Secretion

Lostaprolol engages mechanisms that regulate the renin-angiotensin-aldosterone system (RAAS) by blocking beta1-receptors on juxtaglomerular cells in the kidneys. This pathway effect results in a reduction in renin release, which modifies the systemic signaling associated with vasoregulatory control.

Dosage and Administration Information

How to Use Lostaprolol

Lostaprolol (Bisoprolol fumarate) is administered exclusively via the oral route as a solid film-coated tablet, consistent with its use as a long-term cardiovascular stabilizing agent. The typical usage pattern involves once-daily dosing, generally recommended to be taken in the morning. Tablets should be swallowed whole with liquid and may be taken either with or without food.

Official Dosing Regimens

Indication	Starting Dose	Maximum Recommended Dose
Hypertension/Angina Pectoris	5 mg once daily	20 mg once daily
Chronic Stable Heart Failure	1.25 mg once daily	10 mg once daily

For stable chronic heart failure, treatment requires a controlled, stepwise titration phase, starting at 1.25 mg and slowly increasing the dose over several weeks to months, based on clinical tolerability. The maximum recommended daily dose for patients with severe renal or hepatic impairment is restricted to 10 mg and treatment is not recommended for the pediatric population.

Administration Protocol

Lostaprolol is intended for long-term use in chronic conditions. If treatment must be discontinued, the official protocol advises that the dosage must be gradually reduced (tapered) over approximately one to two weeks to avoid acute clinical deterioration. If a dose is missed, it should be taken as soon as it is remembered that day; however, if it is almost time for the next dose, the missed dose should be skipped, and the regular schedule resumed. Doubling the dose is not recommended.

Recent Clinical Evidence

Research evidence / Overview of Studies for Lostaprolol

️ Evidence for Use in Chronic Heart Failure (HFrEF)

Research regarding the use of Lostaprolol in chronic heart failure with reduced pumping function (known as HFrEF) primarily consists of large-scale, international Randomized Controlled Trials (RCTs). These studies were generally conducted on patients who were already stable. Researchers monitored and measured outcomes related to all-cause death, cardiovascular death, and the frequency of hospital stays over observation periods often lasting a year or more.

The findings from these major long-term trials describe patterns observed in the studied populations related to long-term systemic outcomes including measures of death. What remains uncertain is the applicability of this evidence to all heart failure conditions, as research has primarily focused on patients with reduced ejection fraction. Consequently, data for patients with heart failure and preserved ejection fraction (HFpEF) are still emerging.

Evidence for Use in High Blood Pressure (Hypertension)

Research for high blood pressure was evaluated in clinical trials, including comparison studies and those involving inactive controls (placebo). These studies focused on adult populations diagnosed with hypertension, with follow-up durations that were typically short to intermediate term. Research examined outcomes monitoring physiological strain or stress, specifically through measuring changes in systolic and diastolic blood pressure, and monitoring heart rate.

One key research limitation is that the duration of follow-up was limited in many of the trials. Long-term effects and outcomes reflecting major cardiovascular events (such as stroke or heart attack) over many years are not fully established from these shorter-term blood pressure control studies alone. Comparative evidence against all other existing treatment classes is sometimes lacking.

Evidence for Use in Angina and Post-Heart Attack Management

The research for chronic stable angina pectoris was studied for outcomes related to physical discomfort, measuring the frequency of angina episodes. Separately, the post-myocardial infarction (MI) research was observed in systematic reviews and large observational cohort studies. Evidence is limited for patients with preserved LVEF post-MI, and research does not determine whether an individual will respond similarly to the group patterns described in the studies.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Lostaprolol (FAQ)

Q: Why do official documents refer to Lostaprolol by a different chemical name sometimes?

Lostaprolol is the brand or trade name used for the medicine. According to regulatory and official documents, the active chemical substance in the medicine is consistently referred to by its generic name, which is Bisoprolol fumarate.

Q: How quickly is Lostaprolol supposed to start working after I take it?

Official pharmacokinetic data indicates that the medicine reaches its highest concentration in the blood within 2 to 4 hours after you take a dose. Due to its intended function, the therapeutic effect is sustained and is meant to cover a full 24-hour dosing interval.

Q: What is the main difference between Lostaprolol and other similar medicines?

Lostaprolol is officially categorized as a cardioselective beta-blocker. This means that, according to regulatory classification, it primarily targets the beta1-adrenergic receptors, which are mainly located in the heart. This action provides a more focused therapeutic profile compared to older, non-selective beta-blockers.

Q: What is the general duration of action for a single dose of Lostaprolol?

Official pharmacokinetic data documents that the half-life of Lostaprolol generally ranges between 9 and 12 hours. This duration of activity supports the medicine’s ability to provide 24-hour therapeutic coverage with a single daily dose.

Q: Does Lostaprolol have to be taken at the same time every day?

Lostaprolol is prescribed for once-daily use. Official dosing guidance indicates that taking the medicine at a consistent time each day is generally followed to help maintain stable levels of the medication in your body.

Q: How does the time of day I take Lostaprolol influence its effect?

The administration protocol generally recommends taking the medicine in the morning. This timing is intended to support the goal of achieving consistent 24-hour therapeutic coverage due to the medicine's documented intermediate half-life.

Q: Is Lostaprolol described as a long-term treatment?

Yes, according to official prescribing information, Lostaprolol is intended for the long-term management of chronic conditions. These approved indications include conditions such as stable heart failure and high blood pressure (hypertension).

Q: Is there a maximum amount of time Lostaprolol is recommended to be taken?

Lostaprolol is indicated for chronic conditions and is intended for long-term use. Official regulatory documents do not specify a set maximum duration of treatment for the approved indications.

Q: Can taking Lostaprolol affect my heart rate or pulse?

Yes, the medicine is fundamentally designed to slow the heart rate, a process called negative chronotropy. Official adverse reaction lists state that bradycardia, or a significantly slow heart rate, is a very common adverse reaction in patients treated for chronic heart failure.

Q: Is it normal to feel more tired when starting Lostaprolol?

Official drug labels classify fatigue and dizziness as common adverse reactions, meaning they are reported in up to 1 in 10 people. These effects are often noted as being transient. This suggests they may be more noticeable at the beginning of the treatment period and could lessen over time.

Q: Do the side effects of Lostaprolol usually go away after a few weeks?

Official documentation notes that some common reactions, specifically dizziness and fatigue, are often described as being transient. This suggests that these particular effects may be most noticeable at the start of treatment and may resolve after a short period.

Q: Can Lostaprolol cause changes in mood or sleep?

Official product information lists sleep problems such as insomnia and mental or mood changes among the reported uncommon or rare side effects. These reactions have included occurrences of depression, confusion, or anxiety in studied populations.

Q: Can I take Lostaprolol if I have a history of depression or mood disorders?

Mental and mood changes, including depression, are listed among the less common or rare reported adverse reactions in official prescribing information.

Q: What happens if I stop taking Lostaprolol suddenly?

Regulatory warnings state that abruptly discontinuing Lostaprolol, especially if a patient has coronary artery disease, is associated with a risk of clinical deterioration. This sudden stop can potentially worsen angina pectoris (chest pain) or lead to a myocardial infarction. Official instructions therefore require that the dosage must be gradually reduced over time.

Q: Is it possible to become dependent on Lostaprolol?

Regulatory documents do not use the specific term 'dependence' in relation to this medicine. However, official warnings note that stopping the medicine suddenly may cause clinical deterioration, which is why a dose taper is required when treatment ends.

Q: Are there any special warnings listed for patients with lung conditions using Lostaprolol?

Lostaprolol is formally contraindicated in patients with severe bronchial asthma or severe chronic obstructive pulmonary disease (COPD) due to the risk of bronchospasm. Caution is required even in less severe lung conditions.

Q: Can people with diabetes be prescribed Lostaprolol?

Official regulatory documents describe the use of Lostaprolol in patients with diabetes mellitus as requiring special caution. This is because the medicine may mask the typical warning symptoms of acute hypoglycemia (very low blood sugar), such as a fast heart rate.

Q: What does the FDA or EMA say about Lostaprolol for children?

According to official regulatory documents, the safety and efficacy have not been established in the pediatric population. Due to this lack of data, the use of the medicine in children is officially not recommended.

Q: What is the evidence regarding Lostaprolol and liver function?

Regulatory information highlights that patients with severe hepatic (liver) impairment may have slower clearance of Lostaprolol from the body. Because of this decreased clearance, dose adjustment or close monitoring of the patient is typically advised.

Q: Is Lostaprolol safe to use during pregnancy or while breastfeeding?

Use during pregnancy is generally not recommended unless a health professional determines the potential benefit outweighs the documented risk to the unborn child. Official documents also state that use during breastfeeding is generally not advised.

Q: How is Lostaprolol described in official sources regarding alcohol use?

Official warnings state that alcohol can increase the effects of Lostaprolol. This combination may lead to an additive blood pressure-lowering effect, potentially causing increased dizziness or lightheadedness.

Q: Are there any known interactions between Lostaprolol and over-the-counter pain relievers?

Official documents describe documented interactions with non-steroidal anti-inflammatory drugs (NSAIDs), which include some common over-the-counter pain relievers. The combination may cause the blood pressure-lowering effect of Lostaprolol to be decreased.

Q: Is it described that Lostaprolol can cause changes to potassium levels?

Official documents do not list potassium changes as a common side effect of Lostaprolol alone. However, the medicine works by reducing renin release, which is part of the body's system that regulates potassium and other electrolytes.

Q: What is the official classification of Lostaprolol regarding driving and operating machinery?

Official documents state that side effects like dizziness and fatigue may impair a person's ability to drive or operate machinery. This is particularly noted at the beginning of treatment, when doses are changed, or when the medicine is combined with alcohol.

Q: What kind of studies support the use of Lostaprolol?

The medicine’s use is supported by an array of clinical trials. These include large-scale Randomized Controlled Trials (RCTs) for heart failure and comparison studies for high blood pressure, focusing on outcomes such as blood pressure control and long-term systemic effects.

Q: Is Lostaprolol available as a generic medicine?

Yes, the active ingredient in Lostaprolol, known as Bisoprolol fumarate, is widely listed in government drug databases and is available as a generic medicine in many regions.

Q: Do I need to get blood tests done regularly while taking Lostaprolol?

The need for regular monitoring through blood tests is not specified as a mandatory schedule for all patients. However, monitoring is implied for patients with severe kidney or liver dysfunction, and for diabetic patients, due to the drug’s effects on these systems.

Q: What specific laboratory tests are mentioned in official documents for monitoring Lostaprolol use?

Official documents note that changes in some blood values have been reported, including blood urea nitrogen (BUN), creatinine, and glucose. It is specifically advised that diabetic patients may need regular checking of their blood sugar.

How should Lostaprolol be stored and disposed of?

How to Store and Dispose of Lostaprolol?

The storage and disposal of Lostaprolol (Bisoprolol fumarate) must strictly follow the conditions outlined in the official regulatory documents to maintain product integrity and ensure proper pharmaceutical waste management.

Storage Requirements

Condition	Requirement
Temperature	Store at room temperature, generally between 20°C and 25°C, and ensure the temperature remains below 30°C. Do not freeze.
Protection	Keep the medicine in its original, tightly closed container and protect it from excessive heat, light, and moisture.
Child Safety	The product must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Lostaprolol must not be disposed of in household waste or discharged into sewer systems. Disposal must be completed in accordance with local regulatory requirements for pharmaceutical waste. Patients should consult their pharmacist or local waste authority for proper collection instructions.

Lostaprolol